NVRO - Nevro Corp. Stock Price, News & Analysis

$78.06 1.23 (1.60 %)
(As of 11/23/2017 04:43 AM ET)
Previous Close$76.83
Today's Range$76.46 - $79.00
52-Week Range$65.82 - $99.63
Volume387,300 shs
Average Volume511,112 shs
Market Capitalization$2.28 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.7

About Nevro Corp. (NYSE:NVRO)

Nevro Corp. logoNevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia. HF10 therapy relies on consistent anatomical lead placement. As of December 31, 2016, it was investigating the use of HF10 therapy to address additional indications, such as chronic upper limb and neck pain, painful neuropathies and non-surgical refractory back pain. The Senza system is approved to create electrical impulses from 2 hertz (Hz) to 10,000 Hz.


Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVRO
CUSIPN/A

Debt

Debt-to-Equity Ratio0.59%
Current Ratio8.78%
Quick Ratio6.81%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$228.50 million
Price / Sales10.12
Cash FlowN/A
Price / CashN/A
Book Value$8.24 per share
Price / Book9.47

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($1.45)
Net Income$-31,770,000.00
Net Margins-14.09%
Return on Equity-17.27%
Return on Assets-9.88%

Miscellaneous

Employees518
Outstanding Shares29,630,000

Frequently Asked Questions for Nevro Corp. (NYSE:NVRO)

What is Nevro Corp.'s stock symbol?

Nevro Corp. trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

How were Nevro Corp.'s earnings last quarter?

Nevro Corp. (NYSE:NVRO) announced its earnings results on Monday, November, 6th. The medical equipment provider reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.02. The medical equipment provider had revenue of $82.26 million for the quarter, compared to analysts' expectations of $80.50 million. Nevro Corp. had a negative net margin of 14.09% and a negative return on equity of 17.27%. The company's quarterly revenue was up 35.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.14) EPS. View Nevro Corp.'s Earnings History.

When will Nevro Corp. make its next earnings announcement?

Nevro Corp. is scheduled to release their next quarterly earnings announcement on Thursday, February, 22nd 2018. View Earnings Estimates for Nevro Corp..

Where is Nevro Corp.'s stock going? Where will Nevro Corp.'s stock price be in 2017?

7 brokers have issued twelve-month target prices for Nevro Corp.'s stock. Their predictions range from $85.00 to $110.00. On average, they expect Nevro Corp.'s stock price to reach $100.57 in the next twelve months. View Analyst Ratings for Nevro Corp..

What are Wall Street analysts saying about Nevro Corp. stock?

Here are some recent quotes from research analysts about Nevro Corp. stock:

  • 1. According to Zacks Investment Research, "Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza (R) spinal cord stimulation (SCS) system for the treatment of chronic pain. Senza, HF10, Nevro and the Nevro logo are trademarks of the company. Nevro Corp. is headquartered in Menlo Park, California. " (10/24/2017)
  • 2. Northland Securities analysts commented, "The widely awaited release of Boston Scientific's ACCELERATE Study data on the Q4 call today, was a downer. Strangely enough, the company stated on its call that it "would continue enrolling patients in the trial, expects enrollment to finish by end of FY17, and data release by mid-2018." Suffice it to say, the anti-climax will be perceived as something being off in the ACCELERATE Study, hence being positive for Nevro."The analyst speculated that something is off in the ACCELERATE study, causing a delay in datarelease. Here are some thoughts / questions:Is Boston Sci increasing the sample size in the trial ?Was there a sub-group analysis done and investigators realized that the bellcurve on lead placements was not on T8 - T10 locations, hence pain relief was sub-optimal? Will there now be more anatomical placement on T8 - T10 with its HF arm? In essence, is Boston Sci converging on Nevro's "secret sauce" (2/2/2017)

Who are some of Nevro Corp.'s key competitors?

Who are Nevro Corp.'s key executives?

Nevro Corp.'s management team includes the folowing people:

  • Rami Elghandour, President, Chief Executive Officer (Age 38)
  • Andrew H. Galligan, Chief Financial Officer (Age 61)
  • Patrick Schmitz, Vice President - Operations (Age 57)
  • Michael Enxing, Vice President of Sales (Age 50)
  • Douglas A. Alleavitch, Vice President - Quality and Operations (Age 56)
  • Christopher Christoforou, Vice President - Research and Development (Age 47)
  • Ali Behbahani M.D., Independent Director (Age 40)
  • Lisa D. Earnhardt, Independent Director (Age 47)
  • Frank M. Fischer, Independent Director (Age 75)
  • Wilfred E. Jaeger M.D., Independent Director (Age 61)

Who owns Nevro Corp. stock?

Nevro Corp.'s stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (4.22%), Wells Fargo & Company MN (3.65%), Frontier Capital Management Co. LLC (2.59%), Zevenbergen Capital Investments LLC (2.09%), Point72 Asset Management L.P. (1.83%) and Orbimed Advisors LLC (1.67%). Company insiders that own Nevro Corp. stock include Andre Walker, Andrew H Galligan, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro Corp..

Who sold Nevro Corp. stock? Who is selling Nevro Corp. stock?

Nevro Corp.'s stock was sold by a variety of institutional investors in the last quarter, including Myriad Asset Management Ltd., American Century Companies Inc., Janus Henderson Group PLC, Oak Ridge Investments LLC, Kornitzer Capital Management Inc. KS, Asymmetry Capital Management L.P., Thornburg Investment Management Inc. and Orbimed Advisors LLC. Company insiders that have sold Nevro Corp. company stock in the last year include Andrew H Galligan, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Insider Buying and Selling for Nevro Corp..

Who bought Nevro Corp. stock? Who is buying Nevro Corp. stock?

Nevro Corp.'s stock was acquired by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Principal Financial Group Inc., Point72 Asset Management L.P., Wells Fargo & Company MN, Tygh Capital Management Inc., Artemis Investment Management LLP, Pictet Asset Management Ltd. and Tirschwell & Loewy Inc.. View Insider Buying and Selling for Nevro Corp..

How do I buy Nevro Corp. stock?

Shares of Nevro Corp. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nevro Corp.'s stock price today?

One share of Nevro Corp. stock can currently be purchased for approximately $78.06.

How big of a company is Nevro Corp.?

Nevro Corp. has a market capitalization of $2.28 billion and generates $228.50 million in revenue each year. The medical equipment provider earns $-31,770,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Nevro Corp. employs 518 workers across the globe.

How can I contact Nevro Corp.?

Nevro Corp.'s mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]


MarketBeat Community Rating for Nevro Corp. (NVRO)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  261 (Vote Outperform)
Underperform Votes:  116 (Vote Underperform)
Total Votes:  377
MarketBeat's community ratings are surveys of what our community members think about Nevro Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Nevro Corp. (NYSE:NVRO)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 6 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $100.57 (28.84% upside)

Consensus Price Target History for Nevro Corp. (NYSE:NVRO)

Price Target History for Nevro Corp. (NYSE:NVRO)

Analysts' Ratings History for Nevro Corp. (NYSE:NVRO)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/7/2017Canaccord GenuityLower Price TargetBuy$120.00 -> $110.00N/AView Rating Details
11/7/2017Northland SecuritiesReiterated RatingBuy$96.00N/AView Rating Details
11/7/2017Leerink SwannReiterated RatingOutperform$105.00 -> $110.00N/AView Rating Details
9/1/2017BMO Capital MarketsReiterated RatingBuy$106.00N/AView Rating Details
8/8/2017Morgan StanleyBoost Price TargetOverweight$87.00 -> $95.00MediumView Rating Details
7/3/2017J P Morgan Chase & CoReiterated RatingOverweight$102.00LowView Rating Details
5/14/2017B. RileyDowngradeNeutral$85.00LowView Rating Details
8/11/2016Piper Jaffray CompaniesReiterated RatingOverweight$98.00 -> $112.00N/AView Rating Details
8/9/2016JMP SecuritiesBoost Price TargetMarket Outperform$90.00 -> $110.00N/AView Rating Details
8/8/2016Bank of America CorporationInitiated CoverageBuy$100.00N/AView Rating Details
7/18/2016William BlairReiterated RatingOutperformN/AView Rating Details
7/12/2016Wells Fargo & CompanyInitiated CoverageOutperformN/AView Rating Details
5/16/2016Sterne Agee CRTReiterated RatingBuyN/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Nevro Corp. (NYSE:NVRO)

Earnings by Quarter for Nevro Corp. (NYSE:NVRO)

Earnings History by Quarter for Nevro Corp. (NYSE NVRO)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2018        
11/6/2017Q3 2017($0.23)($0.21)$80.50 million$82.26 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.29)($0.40)$77.75 million$78.02 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.26)($0.50)$68.71 million$68.40 millionViewListenView Earnings Details
2/23/2017Q416($0.20)($0.34)$66.41 million$70.50 millionViewN/AView Earnings Details
11/7/2016Q316($0.39)($0.14)$58.05 million$60.92 millionViewListenView Earnings Details
8/8/2016Q216($0.47)($0.31)$45.11 million$55.40 millionViewN/AView Earnings Details
5/9/2016Q116($0.65)($0.33)$33.48 million$41.65 millionViewN/AView Earnings Details
2/29/2016Q415($0.56)($0.51)$32.88 million$33.10 millionViewListenView Earnings Details
11/9/2015Q315($0.75)($0.70)$12.51 million$15.40 millionViewN/AView Earnings Details
8/6/2015Q215($0.89)($0.77)$9.65 million$11.40 millionViewN/AView Earnings Details
5/11/2015Q1($0.54)($0.57)$8.20 million$9.66 millionViewListenView Earnings Details
3/18/2015Q4 2014($0.51)($0.59)$9.72 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nevro Corp. (NYSE:NVRO)
Current Year EPS Consensus Estimate: $-1.27 EPS
Next Year EPS Consensus Estimate: $-0.41 EPS

Dividends

Dividend History for Nevro Corp. (NYSE:NVRO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Nevro Corp. (NYSE NVRO)

Insider Ownership Percentage: 12.10%
Insider Trades by Quarter for Nevro Corp. (NYSE:NVRO)
Institutional Ownership by Quarter for Nevro Corp. (NYSE:NVRO)

Insider Trades by Quarter for Nevro Corp. (NYSE NVRO)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/14/2017Andrew H GalliganCFOSell7,000$75.11$525,770.00View SEC Filing  
10/5/2017Michael F DemaneDirectorSell5,000$93.50$467,500.00View SEC Filing  
9/27/2017Michael F. DemaneDirectorSell5,000$91.50$457,500.00View SEC Filing  
9/14/2017Wilfred E JaegerDirectorSell16,467$90.19$1,485,158.73View SEC Filing  
9/13/2017Michael F. DemaneDirectorSell5,000$89.50$447,500.00View SEC Filing  
9/11/2017Michael F. DemaneDirectorSell25,000$87.73$2,193,250.00View SEC Filing  
8/24/2017Wilfred E JaegerDirectorSell52,520$86.11$4,522,497.20View SEC Filing  
8/21/2017Wilfred E JaegerDirectorSell40,343$84.28$3,400,108.04View SEC Filing  
8/16/2017Wilfred E. JaegerDirectorSell79,657$82.74$6,590,820.18View SEC Filing  
8/15/2017Wilfred E. JaegerDirectorSell29,665$82.54$2,448,549.10View SEC Filing  
8/14/2017Andrew H. GalliganCFOSell7,000$82.31$576,170.00View SEC Filing  
8/14/2017Wilfred E. JaegerDirectorSell25,255$82.40$2,081,012.00View SEC Filing  
5/15/2017Andrew H. GalliganCFOSell7,500$75.30$564,750.00View SEC Filing  
5/2/2017Michael F DemaneDirectorSell29,800$96.07$2,862,886.00View SEC Filing  
5/1/2017Rami ElghandourCEOSell10,000$95.03$950,300.00View SEC Filing  
4/4/2017Michael EnxingVPSell1,500$93.53$140,295.00View SEC Filing  
4/4/2017Michael F DemaneDirectorSell22,200$93.39$2,073,258.00View SEC Filing  
4/3/2017Andrew H. GalliganCFOSell30,000$94.46$2,833,800.00View SEC Filing  
3/6/2017Michael EnxingVPSell38,500$91.01$3,503,885.00View SEC Filing  
3/3/2017Wilfred E JaegerDirectorSell43,980$95.03$4,179,419.40View SEC Filing  
1/4/2017Michael EnxingVPSell1,500$75.88$113,820.00View SEC Filing  
12/5/2016Michael EnxingVPSell1,500$76.38$114,570.00View SEC Filing  
11/15/2016Andrew H GalliganCFOSell7,500$86.90$651,750.00View SEC Filing  
10/10/2016Rami ElghandourCEOSell3,000$100.00$300,000.00View SEC Filing  
10/6/2016Michael F DemaneDirectorSell139,514$97.46$13,597,034.44View SEC Filing  
10/4/2016Michael EnxingVPSell1,500$99.31$148,965.00View SEC Filing  
8/22/2016Doug AlleavitchVPSell3,000$100.00$300,000.00View SEC Filing  
8/22/2016Wilfred E JaegerDirectorSell154,840$97.79$15,141,803.60View SEC Filing  
8/17/2016Wilfred E JaegerDirectorSell155,160$97.31$15,098,619.60View SEC Filing  
8/15/2016Andrew H GalliganCFOSell7,500$97.71$732,825.00View SEC Filing  
8/10/2016Doug AlleavitchVPSell2,500$95.00$237,500.00View SEC Filing  
8/9/2016Michael F DemaneDirectorSell26,667$91.50$2,440,030.50View SEC Filing  
8/4/2016Michael EnxingVPSell1,500$82.06$123,090.00View SEC Filing  
7/29/2016Doug AlleavitchVPSell1,000$85.00$85,000.00View SEC Filing  
7/29/2016Michael F DemaneDirectorSell13,333$84.00$1,119,972.00View SEC Filing  
7/11/2016Doug AlleavitchVPSell2,000$80.00$160,000.00View SEC Filing  
7/11/2016Michael F DemaneDirectorSell13,333$79.00$1,053,307.00View SEC Filing  
7/5/2016Michael EnxingVPSell1,500$75.39$113,085.00View SEC Filing  
7/1/2016Michael F DemaneDirectorSell13,333$74.00$986,642.00View SEC Filing  
6/8/2016Doug AlleavitchVPSell1,000$75.00$75,000.00View SEC Filing  
6/8/2016Rami ElghandourCEOSell7,000$76.59$536,130.00View SEC Filing  
6/6/2016Michael EnxingVPSell1,500$73.29$109,935.00View SEC Filing  
6/2/2016Andre WalkerVPSell4,000$73.50$294,000.00View SEC Filing  
6/1/2016Doug AlleavitchVPSell500$72.00$36,000.00View SEC Filing  
5/18/2016Wilfred E JaegerDirectorSell112,983$64.68$7,307,740.44View SEC Filing  
5/16/2016Andrew H GalliganCFOSell10,000$64.78$647,800.00View SEC Filing  
5/16/2016Michael F DemaneCEOSell39,999$64.77$2,590,735.23View SEC Filing  
5/12/2016Rami ElghandourPresidentSell7,000$63.93$447,510.00View SEC Filing  
5/4/2016Michael EnxingVPSell1,500$65.06$97,590.00View SEC Filing  
4/4/2016Michael EnxingVPSell8,767$61.59$539,959.53View SEC Filing  
4/1/2016Rami ElghandourPresidentSell7,000$60.99$426,930.00View SEC Filing  
1/11/2016Andre WalkerVPSell7,987$70.75$565,080.25View SEC Filing  
1/4/2016Doug AlleavitchVPSell2,514$66.47$167,105.58View SEC Filing  
12/17/2015Andre WalkerVPSell13$69.00$897.00View SEC Filing  
12/7/2015Rami ElghandourPresidentSell3,500$61.82$216,370.00View SEC Filing  
12/2/2015Andre WalkerVPSell1,000$64.00$64,000.00View SEC Filing  
12/1/2015Andre WalkerVPSell8,000$59.50$476,000.00View SEC Filing  
11/30/2015Andre WalkerVPSell6,000$58.50$351,000.00View SEC Filing  
11/30/2015Rami ElghandourPresidentSell3,500$60.00$210,000.00View SEC Filing  
11/24/2015Andre WalkerVPSell1,000$55.00$55,000.00View SEC Filing  
11/23/2015Andre WalkerVPSell1,000$54.00$54,000.00View SEC Filing  
11/23/2015Wilfred E JaegerDirectorSell25,000$53.48$1,337,000.00View SEC Filing  
11/18/2015Wilfred E JaegerDirectorSell175,000$52.24$9,142,000.00View SEC Filing  
11/16/2015Michael F DemaneCEOSell26,667$50.52$1,347,216.84View SEC Filing  
11/13/2015Brad ValeDirectorBuy2,000$50.76$101,520.00View SEC Filing  
9/17/2015Andre WalkerVPSell4,000$50.75$203,000.00View SEC Filing  
9/2/2015Michael F DemaneCEOSell40,001$45.11$1,804,445.11View SEC Filing  
6/8/2015& Johnson JohnsonMajor ShareholderSell1,010,265$47.94$48,432,104.10View SEC Filing  
6/8/2015Bay City Capital LlcInsiderSell491,835$47.94$23,578,569.90View SEC Filing  
6/8/2015Wilfred E JaegerDirectorSell393,468$47.94$18,862,855.92View SEC Filing  
11/12/2014& Johnson JohnsonMajor ShareholderBuy40,000$18.00$720,000.00View SEC Filing  
11/12/2014A/S NovoInsiderBuy215,000$18.00$3,870,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Nevro Corp. (NYSE NVRO)

Source:
DateHeadline
Nevro Corp. (NVRO) Expected to Announce Quarterly Sales of $90.45 MillionNevro Corp. (NVRO) Expected to Announce Quarterly Sales of $90.45 Million
www.americanbankingnews.com - November 22 at 9:08 AM
-$0.17 Earnings Per Share Expected for Nevro Corp. (NVRO) This Quarter-$0.17 Earnings Per Share Expected for Nevro Corp. (NVRO) This Quarter
www.americanbankingnews.com - November 20 at 7:40 AM
Insider Selling: Nevro Corp. (NVRO) CFO Sells 7,000 Shares of StockInsider Selling: Nevro Corp. (NVRO) CFO Sells 7,000 Shares of Stock
www.americanbankingnews.com - November 16 at 8:10 PM
Analyzing West Pharmaceutical Services (WST) and Nevro Corp. (NVRO)Analyzing West Pharmaceutical Services (WST) and Nevro Corp. (NVRO)
www.americanbankingnews.com - November 9 at 11:48 AM
Critical Contrast: Lombard Medical (EVAR) and Nevro Corp. (NVRO)Critical Contrast: Lombard Medical (EVAR) and Nevro Corp. (NVRO)
www.americanbankingnews.com - November 8 at 3:10 AM
Nevros (NVRO) CEO Rami Elghandour on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaNevro's (NVRO) CEO Rami Elghandour on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 8 at 2:46 AM
Nevro Corp. (NVRO) PT Lowered to $110.00Nevro Corp. (NVRO) PT Lowered to $110.00
www.americanbankingnews.com - November 7 at 9:06 PM
Nevro Corp. (NVRO) Earns "Outperform" Rating from Leerink SwannNevro Corp. (NVRO) Earns "Outperform" Rating from Leerink Swann
www.americanbankingnews.com - November 7 at 12:08 PM
Nevro Corp. (NVRO) Earns "Buy" Rating from Northland SecuritiesNevro Corp. (NVRO) Earns "Buy" Rating from Northland Securities
www.americanbankingnews.com - November 7 at 11:33 AM
Nevro Corp. to Host Earnings CallNevro Corp. to Host Earnings Call
finance.yahoo.com - November 7 at 7:59 AM
Nevro Reports Third Quarter 2017 Financial ResultsNevro Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 7:59 AM
Edited Transcript of NVRO earnings conference call or presentation 6-Nov-17 9:30pm GMTEdited Transcript of NVRO earnings conference call or presentation 6-Nov-17 9:30pm GMT
finance.yahoo.com - November 7 at 7:59 AM
Nevro Corp. (NVRO) Issues Quarterly  Earnings Results, Beats Estimates By $0.01 EPSNevro Corp. (NVRO) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - November 6 at 8:12 PM
Nevro Corp. (NVRO) Given Consensus Recommendation of "Hold" by AnalystsNevro Corp. (NVRO) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 5 at 5:52 AM
Nevro Corp. (NVRO) Expected to Announce Quarterly Sales of $79.91 MillionNevro Corp. (NVRO) Expected to Announce Quarterly Sales of $79.91 Million
www.americanbankingnews.com - November 1 at 3:54 AM
Zacks: Analysts Expect Nevro Corp. (NVRO) to Announce -$0.23 Earnings Per ShareZacks: Analysts Expect Nevro Corp. (NVRO) to Announce -$0.23 Earnings Per Share
www.americanbankingnews.com - October 30 at 7:22 PM
Nevro Corp. (NVRO) to Release Earnings on MondayNevro Corp. (NVRO) to Release Earnings on Monday
www.americanbankingnews.com - October 30 at 10:43 AM
Nevro Corp. (NVRO) Downgraded by BidaskClub to "Sell"Nevro Corp. (NVRO) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - October 28 at 7:34 AM
Nevro Corp. breached its 50 day moving average in a Bearish Manner : NVRO-US : October 26, 2017Nevro Corp. breached its 50 day moving average in a Bearish Manner : NVRO-US : October 26, 2017
finance.yahoo.com - October 27 at 8:50 AM
ETFs with exposure to Nevro Corp. : October 24, 2017ETFs with exposure to Nevro Corp. : October 24, 2017
finance.yahoo.com - October 25 at 8:25 AM
Nevro Corp. (NVRO) vs. Its Peers Financial AnalysisNevro Corp. (NVRO) vs. Its Peers Financial Analysis
www.americanbankingnews.com - October 25 at 7:14 AM
Nevro to Report Operating Results for the Third Quarter 2017Nevro to Report Operating Results for the Third Quarter 2017
finance.yahoo.com - October 24 at 7:54 AM
Nevro Corp. (NVRO) & Its Competitors Critical SurveyNevro Corp. (NVRO) & Its Competitors Critical Survey
www.americanbankingnews.com - October 22 at 6:22 AM
Zacks Investment Research Lowers Nevro Corp. (NVRO) to SellZacks Investment Research Lowers Nevro Corp. (NVRO) to Sell
www.americanbankingnews.com - October 16 at 12:14 AM
ETFs with exposure to Nevro Corp. : October 13, 2017ETFs with exposure to Nevro Corp. : October 13, 2017
finance.yahoo.com - October 14 at 6:17 AM
-$0.23 EPS Expected for Nevro Corp. (NVRO) This Quarter-$0.23 EPS Expected for Nevro Corp. (NVRO) This Quarter
www.americanbankingnews.com - October 11 at 6:16 PM
Nevro Corp. (NVRO) Receives Average Recommendation of "Hold" from BrokeragesNevro Corp. (NVRO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 11 at 8:49 AM
Nevro Corp. (NVRO) Director Michael F. Demane Sells 5,000 SharesNevro Corp. (NVRO) Director Michael F. Demane Sells 5,000 Shares
www.americanbankingnews.com - October 10 at 1:32 PM
Nevro Corp. (NVRO) Earns "Buy" Rating from Canaccord GenuityNevro Corp. (NVRO) Earns "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - October 9 at 2:34 PM
Nevro Corp. (NVRO) Upgraded at BidaskClubNevro Corp. (NVRO) Upgraded at BidaskClub
www.americanbankingnews.com - October 7 at 10:44 AM
Reviewing Meridian Bioscience (VIVO) and Nevro Corp. (NVRO)Reviewing Meridian Bioscience (VIVO) and Nevro Corp. (NVRO)
www.americanbankingnews.com - October 4 at 4:32 AM
ETFs with exposure to Nevro Corp. : October 2, 2017ETFs with exposure to Nevro Corp. : October 2, 2017
finance.yahoo.com - October 2 at 7:20 PM
Michael F. Demane Sells 5,000 Shares of Nevro Corp. (NVRO) StockMichael F. Demane Sells 5,000 Shares of Nevro Corp. (NVRO) Stock
www.americanbankingnews.com - September 28 at 7:48 PM
Critical Analysis: Nevro Corp. (NVRO) vs. Its PeersCritical Analysis: Nevro Corp. (NVRO) vs. Its Peers
www.americanbankingnews.com - September 28 at 2:28 PM
Analyzing C.R. Bard (BCR) and Nevro Corp. (NVRO)Analyzing C.R. Bard (BCR) and Nevro Corp. (NVRO)
www.americanbankingnews.com - September 26 at 7:24 AM
 Analysts Anticipate Nevro Corp. (NVRO) Will Post Quarterly Sales of $79.51 Million Analysts Anticipate Nevro Corp. (NVRO) Will Post Quarterly Sales of $79.51 Million
www.americanbankingnews.com - September 25 at 9:56 AM
Nevro Corp. (NVRO) & SeaSpine Holdings Corporation (SPNE) Critical AnalysisNevro Corp. (NVRO) & SeaSpine Holdings Corporation (SPNE) Critical Analysis
www.americanbankingnews.com - September 19 at 12:48 AM
Nevro Corp. (NVRO) Director Wilfred E. Jaeger Sells 16,467 SharesNevro Corp. (NVRO) Director Wilfred E. Jaeger Sells 16,467 Shares
www.americanbankingnews.com - September 18 at 7:24 PM
Nevro Corp. (NVRO) Given Consensus Rating of "Hold" by BrokeragesNevro Corp. (NVRO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 16 at 6:36 AM
Nevro Gets Relative Strength Rating UpgradeNevro Gets Relative Strength Rating Upgrade
finance.yahoo.com - September 15 at 7:01 AM
Insider Selling: Nevro Corp. (NVRO) Director Sells 5,000 Shares of StockInsider Selling: Nevro Corp. (NVRO) Director Sells 5,000 Shares of Stock
www.americanbankingnews.com - September 14 at 11:16 PM
Michael F. Demane Sells 25,000 Shares of Nevro Corp. (NVRO) StockMichael F. Demane Sells 25,000 Shares of Nevro Corp. (NVRO) Stock
www.americanbankingnews.com - September 13 at 4:14 PM
Stocks Generating Improved Relative Strength: NevroStocks Generating Improved Relative Strength: Nevro
finance.yahoo.com - September 12 at 7:18 AM
Nevro Corp. (NVRO) Expected to Announce Quarterly Sales of $79.51 MillionNevro Corp. (NVRO) Expected to Announce Quarterly Sales of $79.51 Million
www.americanbankingnews.com - September 6 at 7:52 AM
Nevro Corp. (NVRO) Given "Buy" Rating at BMO Capital MarketsNevro Corp. (NVRO) Given "Buy" Rating at BMO Capital Markets
www.americanbankingnews.com - September 2 at 10:38 AM
Nevro to Present at Upcoming Investor ConferencesNevro to Present at Upcoming Investor Conferences
finance.yahoo.com - August 25 at 9:24 AM
Nevro Corp. (NVRO) Director Sells $4,522,497.20 in StockNevro Corp. (NVRO) Director Sells $4,522,497.20 in Stock
www.americanbankingnews.com - August 24 at 10:17 PM
Nevro Corp. (NVRO) Receives Consensus Recommendation of "Hold" from AnalystsNevro Corp. (NVRO) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 22 at 9:08 AM
Nevro Corp. (NVRO) Director Wilfred E. Jaeger Sells 40,343 SharesNevro Corp. (NVRO) Director Wilfred E. Jaeger Sells 40,343 Shares
www.americanbankingnews.com - August 21 at 7:26 PM
Nevro Corp. (NVRO) Expected to Post Quarterly Sales of $79.51 MillionNevro Corp. (NVRO) Expected to Post Quarterly Sales of $79.51 Million
www.americanbankingnews.com - August 18 at 3:50 AM

Social Media

Financials

Chart

Nevro Corp. (NYSE NVRO) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.